Retatrutide Lawsuit Myth vs. FDA's Real Enforcement File

No Eli Lilly civil lawsuit over retatrutide exists; the suits that dominate this search term are tirzepatide cases. The live instrument against retatrutide sellers is FDA's September 9, 2025 warning letter wave, and it describes an exemption failure no litigation outcome or shortage resolution can reverse.

Buyers searching "retatrutide lawsuit" this quarter are being routed to the wrong document set. The civil complaints that rank for the term — Strive Pharmacy, Empower, Willow Health, Mochi Health — are tirzepatide cases brought by Eli Lilly and Company over compounded tirzepatide marketing. None of them alleges anything about retatrutide. The instrument that actually reaches a retatrutide seller is a batch of FDA warning letters dated September 9, 2025, and the statutory theory in those letters is materially worse for a supply chain than any patent or false-advertising complaint, because it does not depend on a shortage, a court's standing analysis, or a brand's litigation appetite.^8,2,3

What the search term actually returns versus what is on the docket

Lilly's civil program against compounders is real, well-funded, and narrowly aimed. The company has sued compounding pharmacies and telehealth platforms including Strive Pharmacy, Empower, Willow Health, and Mochi Health, alleging false marketing of compounded tirzepatide. It has also sued two pharmacies over compounded tirzepatide marketing claims and intervened in the Outsourcing Facilities Association's litigation against FDA over tirzepatide compounding exemptions. Every one of those actions is anchored to tirzepatide.^8,1,4

The Mochi Health complaint, dated October 24, 2025, makes the point plainly. Its factual core is tirzepatide supplied at strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, plus corporate-practice-of-medicine allegations about how the platform was structured. There is no retatrutide allegation in it. A purchasing manager who reads that filing as a retatrutide risk disclosure has read a document about a different molecule and a different distribution model.⁸

The document that actually governs retatrutide: FDA's September 9, 2025 warning letter wave

On September 9, 2025, FDA published a batch of warning letters to compounders and marketers offering retatrutide, citing identical statutory defects across recipients. FDA's letter to GLP-1 Solution is indexed as case 715883 and dated September 9, 2025; three further letters published the same day, naming Eli Lilly and Company as the reference brand, are indexed as cases 716485, 716462, and 716475. All four are retrievable from FDA's warning letter database at the URLs listed in this post's sources, and a buyer verifying the case numbers should pull them there rather than take them from a summary. Four letters on one date resting on the same statutory reasoning is consistent with a coordinated program action, though FDA does not characterize the batch that way in the letters themselves.^3,2,7,10

The GLP-1 Solution letter states that compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. That single sentence is the whole exposure. It is not a labeling quibble that a revised web page cures, and it is not a marketing claim dispute that a settlement resolves. It is a finding that the product category has no compounding exemption available to it.³

This wave also was not the agency's first pass. An enforcement roundup dated December 17, 2024 covered four warning letters to companies for introducing unapproved GLP-1 drug products — semaglutide, tirzepatide, and/or retatrutide — into interstate commerce. Retatrutide was already named in that earlier tranche. The September 2025 letters are escalation on a file the agency opened at least nine months earlier.⁹

Why retatrutide has no exemption path at all, unlike tirzepatide

The reasoning in the September 9, 2025 letter is worth reading closely, because it is structural rather than circumstantial. FDA states that retatrutide is not eligible for the 503A exemption because it is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved drug, and does not appear on the 503A bulks list. Separately, FDA states that retatrutide is not eligible for the 503B exemption because it does not appear on the 503B bulks list.³

Three independent gates, and retatrutide fails all three on the 503A side and the only gate on the 503B side. None of those failures is a function of supply conditions. A compendial monograph is written by USP on its own timetable. Inclusion in an FDA-approved drug requires an approval that does not exist. Bulks-list addition is a nomination-and-review process with its own docket. No court and no market event moves any of them.³

Tirzepatide's compounding exposure is a different shape. FDA's Declaratory Order on resolution of the tirzepatide shortage governs when compounders lose exemption eligibility for tirzepatide — meaning tirzepatide had eligibility to lose, contingent on a listing status that can move in either direction. Retatrutide never had that contingency. There is no shortage listing to reopen, because there is no approved product to be short of.^6,3

Why the tirzepatide civil suits keep losing, and why that does not help retatrutide sellers

Lilly's civil record is not a clean sweep. A federal court dismissed the company's lawsuit against Strive Pharmacy for lack of standing. Another judge rejected Lilly's suit against Willow Health, writing that producing large volumes of a compounded medication is not itself unlawful. Both rulings decide questions about a private plaintiff's case, and both are confined to the tirzepatide marketing conduct the complaints described.⁵

They are also irrelevant to the retatrutide file. Standing doctrine constrains a private plaintiff who must show its own injury; FDA needs no such showing to issue a warning letter. A holding that volume alone is not unlawful answers a marketing-conduct theory, not a finding that a compounded product falls outside 503A and 503B entirely. A supplier that cites the Strive dismissal as coverage for retatrutide is answering a question no regulator asked.^5,3

• A dismissal for lack of standing decides who may sue, not whether the underlying product qualified for an exemption.
• The Willow Health reasoning addresses production volume, a fact pattern absent from the September 9, 2025 letters.
• Warning letters are administrative correspondence, not complaints; there is no standing threshold and no adversary to lose to at the outset.
• The Declaratory Order path that gives tirzepatide defendants an argument about timing has no retatrutide analogue.^5,3,6

What re-qualification looks like on a purchase order this quarter

The distinction above is not academic once it reaches a purchase order. A buyer whose risk model was built around Lilly civil litigation has been hedging the wrong instrument, and the documentation package that answers a false-marketing complaint does not answer a 503A/503B eligibility finding. Re-qualification for retatrutide lines should be treated as a separate exercise from tirzepatide lines, with separate paperwork.^3,6

1. Lot-level chain of title: named synthesis site, named fill site, and the date each custody transfer occurred, for every lot in a shipment rather than for the trade name generally.
2. Written label controls: a documented procedure showing research-use-only labeling is applied at fill and verified at release, with the reviewer's name recorded. FDA's December 17, 2024 roundup and the September 2025 wave both turn on how product entered interstate commerce.
3. A written statement from the supplier that it does not hold and does not claim 503A or 503B compounding eligibility for retatrutide, given FDA's finding on monograph status and both bulks lists.
4. Indemnification language that names the 503A/503B eligibility gap specifically, rather than a general representation of regulatory compliance that a supplier can satisfy on paper.
5. Notice covenants requiring disclosure of any FDA correspondence — warning letter, untitled letter, or Form 483 — received by the supplier or its named fill sites, with a fixed reporting window.
6. Segregation of retatrutide inventory in the buyer's own records, so a future enforcement action against one molecule does not require reconstructing which lots of which compound moved where.^3,6,9

Items one and two are the two a quote cycle can test. Chain-of-title records and label-control procedures are byproducts of running a controlled fill operation, so a seller that cannot produce them has not established where the material was made or who applied the label at release — which is the same evidentiary gap the December 17, 2024 letters describe when they address how unapproved product entered interstate commerce. A buyer can put both requests in the request for quote and read the answer before committing volume.^9,3

Pricing the difference between a shortage-contingent risk and a structural one

Procurement organizations routinely price regulatory risk as a single line item across a category. For GLP-1-adjacent research materials that approach is now wrong on its face. Tirzepatide's compounding exposure moves with a listing status that FDA has already addressed by Declaratory Order — a variable with a known mechanism and a known decision-maker. Retatrutide's exposure does not move at all, because the three 503A gates and the single 503B gate close for reasons unrelated to supply.^6,3

That difference belongs in the commercial terms, not in a footnote. A shortage-contingent risk justifies shorter contract terms, price adjustment clauses, and a wait-and-see posture on volume commitments. A structural risk justifies a different insurance conversation, harder indemnity, tighter documentation covenants, and a decision about whether the line belongs in the catalog at the volumes being discussed.^6,9

A buyer could read the Strive and Willow dismissals, together with the absence of any retatrutide complaint, as adding up to a quiet quarter. The dated record does not support that reading. Four letters issued on September 9, 2025 on the same statutory reasoning, following an enforcement roundup dated December 17, 2024 that had already named retatrutide, leave the 503A/503B ineligibility finding standing and unappealed by any of the mechanisms a court can reach.^2,10,5,9